Edwards Lifesciences Stock News

Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) fourth-quarter results.

Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IRVINE, Calif., Jan. 19, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2021 after the market closes on Wednesday, Janu

There are medical emergency times when both a National Emergency and a Personal Emergency must have attention. People skills, facilities, time will be shared to preserve life. Easiest to picture is a

Edwards Lifesciences (EW) closed at $118.26 in the latest trading session, marking a -1.83% move from the prior day.

Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Analysts have provided the following ratings for Edwards Lifesciences (NYSE: EW ) within the last quarter:

We think that Edwards Lifesciences currently is a better pick compared to Seagate Technology. Both companies have similar net income of around $1.5 billion, but Seagates current P/S multiple stands at 2x, while EWs stands at almost 15x. Do these valuations make sense? We think so, and

IRVINE, Calif., Jan. 5, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate at the J.P.

Edwards Lifesciences Corp (EW) shares closed today at 1.0% below its 52 week high of $130.60, giving the company a market cap of $81B. The stock is currently up 43.1% year-to-date, up 47.3% over the past 12 months, and up 319.6% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 56.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 369.5% The company's stock price performance over the past 12 months beats the peer average by 287.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -48.8% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Robust performance across the Critical Care and TAVR businesses is driving the top line for Edwards Lifesciences (EW).

Waldron Private Wealth LLC grew its holdings in Edwards Lifesciences Co. (NYSE:EW) by 32.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 3,653 shares of the medical research companys stock after purchasing an additional 893 shares during the period. Waldron Private Wealth LLCs holdings []

Mount Yale Investment Advisors LLC trimmed its position in Edwards Lifesciences Co. (NYSE:EW) by 9.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,820 shares of the medical research companys stock after selling 976 shares during the quarter. Mount Yale Investment Advisors LLCs []